ObjectiveTo investigate whether blockade of hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels modifies migraine induced by activation of vascular ATP-sensitive potassium (K(ATP)) channels.MethodsWe conducted a single-centre, randomised, double-blind, placebo-controlled, two-way crossover study in adults with migraine without aura. On two separate days, participants received intravenous levcromakalim followed immediately by either oral ivabradine or placebo in a balanced… →

INTRODUCTION: Early identification of patients with high cardiorenal risk and timely targeted interventions are critical in managing type 2 diabetes (T2D). Although we previously developed a multivariable risk score to predict diabetic kidney disease (DKD), its ability to stratify cardiorenal risk in T2D patients with established high cardiovascular risk remains unknown. →

CONCLUSIONS: The results of the FIRST-NIS support Rd as an effective and safe frontline treatment option for patients with TIE NDMM, irrespective of age, with similar clinical outcomes in the real world compared to the pivotal trial. →

Emerging neurotechnologies such as brain-computer interfaces and implantable sensors offer considerable promise in the treatment of a broad range of neurological conditions. The key challenges are reducing the implant size, powering it, and confirming long-term accuracy and safety. Here we report the development of a novel type of implantable medical device that measures intracranial pressure… →

CONCLUSIONS: Implementing Picterus Jaundice Pro yielded encouraging improvements in screening practices, underscoring its potential to advance neonatal care. Addressing systemic barriers and raising awareness among parents and healthcare workers is crucial for maximizing impact. →

CONCLUSION: A significant main effect was observed in response to DN and sham DN local to the intervention site. This finding suggests peripherally mediated shared mechanisms between DN and sham DN. Baseline pain modulatory efficiency and post-intervention expectations may be indicators of individuals who will experience a greater analgesic response to needling interventions. →

BACKGROUND: [^(177)Lu]Lu-prostate-specific membrane antigen (PSMA)-617 (^(177)Lu-PSMA-617) is a novel treatment for metastatic castration-resistant prostate cancer. Here, we aimed to evaluate ^(177)Lu-PSMA-617 in patients with PSMA-expressing oligometastatic hormone-sensitive prostate cancer (HSPC). →
